Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: Possible involvement of antioxidant and nitrergic pathways
Restricted accessResearch articleFirst published online November, 2013
Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: Possible involvement of antioxidant and nitrergic pathways
It has been hypothesized that oxidative imbalance and alterations in nitrergic signaling play a role in the neurobiology of schizophrenia. Preliminary evidence suggests that adjunctive minocycline treatment is efficacious for cognitive and negative symptoms of schizophrenia. This study investigated the effects of minocycline in the prevention and reversal of ketamine-induced schizophrenia-like behaviors in mice. In the reversal protocol, animals received ketamine (20 mg/kg per day intraperitoneally or saline for 14 days, and minocycline (25 or 50 mg/kg daily), risperidone or vehicle treatment from days 8 to 14. In the prevention protocol, mice were pretreated with minocycline, risperidone or vehicle prior to ketamine. Behaviors related to positive (locomotor activity and prepulse inhibition of startle), negative (social interaction) and cognitive (Y maze) symptoms of schizophrenia were also assessed. Glutathione (GSH), thiobarbituric acid-reactive substances (TBARS) and nitrite levels were measured in the prefrontal cortex, hippocampus and striatum. Minocycline and risperidone prevented and reversed ketamine-induced alterations in behavioral paradigms, oxidative markers (i.e. ketamine-induced decrease and increase in GSH levels and TBARS content, respectively) as well as nitrite levels in the striatum. These data provide a rationale for evaluating minocycline as a novel psychotropic agent and suggest that its mechanism of action includes antioxidant and nitrergic systems.
ArcherJ (1973) Tests for emotionality in rats and mice: A review. Anim Behav21: 205–235.
2.
ArguelloPAGogosJA (2010) Cognition in mouse models of schizophrenia susceptibility genes. Schizophr Bull36: 289–300.
3.
BeckerAGreckschG (2004) Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia. Test of predictive validity. Prog Neuropsychopharmacol Biol Psychiatry28: 1267–1277.
4.
BehrensMMSejnowskiTJ (2009) Does schizophrenia arise from oxidative dysregulation of parvalbumin-interneurons in the developing cortex?Neuropharmacology57: 193–200.
5.
Bubenikova-ValesovaVHoracekJVrajovaM, et al. (2008) Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci Biobehav Rev32: 1014–1023.
6.
BuckleyPFStahlSM (2007) Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac?Acta Psychiatr Scand115: 93–100.
7.
ChatterjeeMVermaRGangulyS, et al. (2012) Neurochemical and molecular characterization of ketamine-induced experimental psychosis model in mice. Neuropharmacology63: 1161–1171.
8.
ChaudhryIBHallakJHusainN, et al. (2012) Minocycline benefits negative symptoms in early schizophrenia: A randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol26: 1185–1193.
9.
ChavesCMarqueCRTrzesniakC, et al. (2009) Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: An update. Braz J Med Biol Res42: 1002–1014.
10.
ChenMOnaVOLiM, et al. (2000) Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med6: 797–801.
11.
ChindoBAAdzuBYahayaTA, et al. (2012) Ketamine-enhanced immobility in forced swim test: A possible animal model for the negative symptoms of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry38: 310–316.
12.
ChoiYKimHSShinKY, et al. (2007) Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer’s disease models. Neuropsychopharmacology32: 2393–2404.
13.
CoyleJT (2013) Nitric oxide and symptom reduction in schizophrenia. JAMA Psychiatry70: 664–665.
14.
Dall’ignaOPFettPGomesMW, et al. (2007) Caffeine and adenosine a(2a) receptor antagonists prevent beta-amyloid (25–35)-induced cognitive deficits in mice. Exp Neurol203: 241–245.
15.
DeanOMData-FrancoJGiorlandoF, et al. (2012) Minocycline: Therapeutic potential in psychiatry. CNS Drugs26: 391–401.
16.
De OliveiraLSpiazziCMBortolinT, et al. (2009) Different sub-anesthetic doses of ketamine increase oxidative stress in the brain of rats. Prog Neuropsychopharmacol Biol Psychiatry33: 1003–1008.
17.
DuYMaZLinS, et al. (2001) Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson’s disease. Proc Natl Acad Sci U S A98: 14669–14674.
18.
DuanTTTanJWYuanQ, et al. (2013) Acute ketamine induces hippocampal synaptic depression and spatial memory impairment through dopamine D1/D5 receptors. Psychopharmacology228: 451–61.
19.
FendtMKochM (2013) Translational value of startle modulations. Cell Tissue Res E-pub ahead of print 23 March 2013. DOI: 10.1007/s00441-013-1599-5.
20.
FujitaYIshimaTKunitachiS, et al. (2008) Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline. Prog Neuropsychopharmacol Biol Psychiatry32: 336–339.
21.
Garrido-MesaNZarzueloAGalvezJ (2013) Minocycline: Far beyond an antibiotic. Br J Pharmacol169: 337–352.
22.
GeyerMAMcilwainKLPaylorR (2002) Mouse genetic models for prepulse inhibition: An early review. Mol Psychiatry7: 1039–1053.
23.
GreenLCTannenbaumSRGoldmanP (1981) Nitrate synthesis in the germfree and conventional rat. Science212: 56–58.
24.
HallakJEMaia-De-OliveiraJPAbraoJ, et al. (2013) Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: A randomized, double-blind, placebo-controlled trial. JAMA Psychiatry70: 668–676.
25.
HashimotoKIshimaT (2010) A novel target of action of minocycline in NGF-induced neurite outgrowth in PC12 cells: Translation initiation factor eIF4AI. PLoS ONE5: e15430.
26.
HattaKSatoKHamakawaH, et al. (2009) Effectiveness of second-generation antipsychotics with acute-phase schizophrenia. Schizophr Res113: 49–55.
27.
HouYZhangHXieG, et al. (2013) Neuronal injury, but not microglia activation, is associated with ketamine-induced experimental schizophrenic model in mice. Prog Neuropsychopharmacol Biol Psychiatry17: 00072–00079.
28.
IntaDMeyer-LindenbergAGassP (2011) Alterations in postnatal neurogenesis and dopamine dysregulation in schizophrenia: A hypothesis. Schizophr Bull37: 674–680.
29.
JavittDCZukinSR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry148: 1301–1308.
30.
JavittDCZukinSRHeresco-LevyU, et al. (2012) Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. Schizophr Bull38: 958–966.
31.
JentschJDRothRH (1999) The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology20: 201–225.
32.
JonesPBBarnesTRDaviesL, et al. (2006) Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry63: 1079–1087.
33.
KamiyamaHMatsumotoMOtaniS, et al. (2011) Mechanisms underlying ketamine-induced synaptic depression in rat hippocampus-medial prefrontal cortex pathway. Neuroscience177: 159–169.
34.
KapurSSeemanP (2002) NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-Ht(2) receptors – implications for models of schizophrenia. Mol Psychiatry7: 837–844.
35.
KeefeRSBilderRMDavisSM, et al. (2007) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry64: 633–647.
36.
KeilhoffGBeckerAGreckschG, et al. (2004) Repeated application of ketamine to rats induces changes in the hippocampal expression of parvalbumin, neuronal nitric oxide synthase and CFOS similar to those found in human schizophrenia. Neuroscience126: 591–598.
37.
KrausRLPasiecznyRLariosa-WillinghamK, et al. (2005) Antioxidant properties of minocycline: Neuroprotection in an oxidative stress assay and direct radical-scavenging activity. J Neurochem94: 819–827.
38.
KulakACuenodMDoKQ (2012) Behavioral phenotyping of glutathione-deficient mice: Relevance to schizophrenia and bipolar disorder. Behav Brain Res226: 563–570.
39.
LarsonMKWalkerEFComptonMT (2010) Early signs, diagnosis and therapeutics of the prodromal phase of schizophrenia and related psychotic disorders. Expert Rev Neurother10: 1347–1359.
40.
LaruelleMKegelesLSAbi-DarghamA (2003) Glutamate, dopamine, and schizophrenia: From pathophysiology to treatment. Ann N Y Acad Sci: 138–158.
41.
LeuchtSBarnesTRKisslingW, et al. (2003) Relapse prevention in schizophrenia with new-generation antipsychotics: A systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry160: 1209–1222.
42.
LevinRCalzavaraMBSantosCM, et al. (2011) Spontaneously hypertensive rats (SHR) present deficits in prepulse inhibition of startle specifically reverted by clozapine. Prog Neuropsychopharmacol Biol Psychiatry35: 1748–1752.
43.
LevkovitzY (2013) Minocycline as an Adjunctive Therapy for Schizophrenia: A Randomized Controlled Study. Bethesda, USA: National Library of Medicine (US): ClinicalTrials.gov (Internet). Available at: http://clinicaltrials.gov/show/NCT01133080 (accessed 24 July 2013).
44.
LevkovitzYLeviUBrawY, et al. (2007) Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia. Brain Res18: 154–162.
45.
LevkovitzYMendlovichSRiwkesS, et al. (2010) A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry71: 138–149.
46.
LiebermanJA (2007) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: Efficacy, safety and cost outcomes of CATIE and other trials. J Clin Psychiatry68: e04.
47.
LorrainDSBacceiCSBristowLJ, et al. (2003) Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: Modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience117: 697–706.
48.
LysakerPHEriksonMMacapagalKR, et al. (2012) Development of personal narratives as a mediator of the impact of deficits in social cognition and social withdrawal on negative symptoms in schizophrenia. J Nerv Ment Dis200: 290–295.
49.
Maia-De-OliveiraJPTrzesniakCOliveiraIR, et al. (2012) Nitric oxide plasma/serum levels in patients with schizophrenia: A systematic review and meta-analysis. Rev Bras Psiquiatria34: s149-s155.
50.
MiyamotoSJarskogLFFleischhackerWW (2013) Alternative pharmacologic targets for the treatment of schizophrenia: Results from phase I and II trials. Curr Opin Psychiatry26: 158–165.
51.
MonjiAKatoTKanbaS (2009) Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci63: 257–265.
52.
NandraKSAgiusM (2012) The differences between typical and atypical antipsychotics: The effects on neurogenesis. Psychiatr Danub24: S95–S99.
53.
NeillJCBarnesSCookS, et al. (2010) Animal models of cognitive dysfunction and negative symptoms of schizophrenia: Focus on NMDA receptor antagonism. Pharmacol Ther128: 419–432.
54.
OhkawaHOhishiNYagiK (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem95: 351–358.
55.
PengZZhangRWangH, et al. (2013) Ziprasidone ameliorates anxiety-like behaviors in a rat model of PTSD and up-regulates neurogenesis in the hippocampus and hippocampus-derived neural stem cells. Behav Brain Res244: 1–8.
56.
RadenovicLSelakovicV (2005) Differential effects of NMDA and AMPA/kainate receptor antagonists on nitric oxide production in rat brain following intrahippocampal injection. Brain Res Bull67: 133–141.
57.
RadyushkinKHammerschmidtKBoretiusS, et al. (2009) Neuroligin-3-deficient mice: Model of a monogenic heritable form of autism with an olfactory deficit. Genes Brain Behav8: 416–425.
58.
RemberkBNamyslowskaIRybakowskiF (2012) Cognition and communication dysfunctions in early-onset schizophrenia: Effect of risperidone. Prog Neuropsychopharmacol Biol Psychiatry39: 348–354.
59.
SchildknechtSPapeRMullerN, et al. (2011) Neuroprotection by minocycline caused by direct and specific scavenging of peroxynitrite. J Biol Chem286: 4991–5002.
60.
SeamansJKYangCR (2004) The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol74: 1–58.
61.
SedlakJLindsayRH (1968) Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman’s reagent. Anal Biochem25: 192–205.
62.
ShamsiSLauALenczT, et al. (2011) Cognitive and symptomatic predictors of functional disability in schizophrenia. Schizophr Res126: 257–264.
63.
SoczynskaJKMansurRBBrietzkeE, et al. (2012) Novel therapeutic targets in depression: Minocycline as a candidate treatment. Behav Brain Res235: 302–317.
64.
StojkovicTRadonjicNVVelimirovicM, et al. (2012) Risperidone reverses phencyclidine induced decrease in glutathione levels and alterations of antioxidant defense in rat brain. Prog Neuropsychopharmacol Biol Psychiatry39: 192–199.
65.
TakahataRMoghaddamB (1998) Glutamatergic regulation of basal and stimulus-activated dopamine release in the prefrontal cortex. J Neurochem71: 1443–1449.
66.
TandonRNasrallahHAKeshavanMS (2009) Schizophrenia, ‘Just the Facts’ 4. Clinical features and conceptualization. Schizophr Res110: 1–23.
67.
TandonRNasrallahHAKeshavanMS (2010) Schizophrenia, ‘Just the Facts’ 5. Treatment and prevention. Past, present, and future. Schizophr Res122: 1–23.
68.
TorreyEFDavisJM (2012) Adjunct treatments for schizophrenia and bipolar disorder: What to try when you are out of ideas. Clin Schizophr Relat Psychoses5: 208–216.
69.
TsaiMCLiouCWLinTK, et al. (2013) Changes in oxidative stress markers in patients with schizophrenia: The effect of antipsychotic drugs. Psychiatry Res13: 00044–00049.
70.
Van Den BuuseM (2010) Modeling the positive symptoms of schizophrenia in genetically modified mice: Pharmacology and methodology aspects. Schizophr Bull36: 246–270.
71.
WestARGraceAA (2000) Striatal nitric oxide signaling regulates the neuronal activity of midbrain dopamine neurons in vivo. J Neurophysiol83: 1796–1808.
72.
WyattRJAlexanderRCEganMF, et al. (1988) Schizophrenia, just the facts. What do we know, how well do we know it?Schizophr Res1: 3–18.
73.
YamadaKNodaYHasegawaT, et al. (1996) The role of nitric oxide in dizocilpine-induced impairment of spontaneous alternation behavior in mice. J Pharmacol Exp Ther276: 460–466.
74.
YeeBKSingerP (2013) A conceptual and practical guide to the behavioural evaluation of animal models of the symptomatology and therapy of schizophrenia. Cell Tissue Res E-pub ahead of print 12 April 2013. DOI 10.1007/s00441-013-1611-0.
75.
ZhangLKitaichiKFujimotoY, et al. (2006) Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine. Prog Neuropsychopharmacol Biol Psychiatry30: 1381–1393.
76.
ZhangLShirayamaYIyoM, et al. (2007) Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology32: 2004–2010.
77.
ZhangXYZhouDFShenYC, et al. (2012) Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia. Neuropharmacology62: 1928–1934.
